| Document |
Document Title |
|
WO/2017/207678A1 |
Wnt-inducible signalling protein 1 (WISP1) or a fragment or variant thereof for use in maintaining or increasing muscle function and/or mass in a subject, and/or substantially preventing or reducing muscle wasting in a subject.
|
|
WO/2017/207600A1 |
The present invention relates to olesoxime for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
|
|
WO/2017/209290A1 |
The present invention provides a method for producing a motor neuron from a pluripotent stem cell, said method comprising the following steps: (1) introducing a single Sendai virus vector carrying a nucleic acid encoding Lhx3, a nucleic ...
|
|
WO/2017/201585A1 |
Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors...
|
|
WO/2017/204277A1 |
The present invention provides an anti-TGF-beta3 antibody and a method of using the antibody. The anti-TGF-beta3 antibody according to the present invention has a binding activity to TGF-beta3 but does not have a neutralizing activity to...
|
|
WO/2017/205101A1 |
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that s...
|
|
WO/2017/203083A1 |
The present invention relates to 1,2,3-triazoles of formula (I), which can be used to improve or restore intracellular calcium homeostasis and RyR-calstabin binding in human and animal cells. The invention also relates to methods for syn...
|
|
WO/2017/199976A1 |
The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition...
|
|
WO/2017/199250A1 |
Isolated cells of a mixed character, possessing a mesenchymal stem cell phenotype and a muscle cell phenotype, as well as extracellular vesicles secreted from same, pharmaceutical compositions comprising same, and methods of treatment co...
|
|
WO/2017/197328A1 |
Enteral Feeding Intolerance (EFI) and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of relamorelin every 8 hours (three times a day). Therapeutic benefit ...
|
|
WO/2017/197107A1 |
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 rec...
|
|
WO/2017/194975A1 |
The invention provides anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providin...
|
|
WO/2017/197131A1 |
Enteral feeding intolerance and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Ulimorelin is administered ...
|
|
WO/2017/193563A1 |
A composition, and an application and pharmaceutical preparation thereof. The invention provides a plurality of novel compositions and preparations comprising a berberine in combination with EPA and DHA, and an application thereof for tr...
|
|
WO/2017/190708A1 |
Provided in the present invention are a compound as represented by formula (I), a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, and a hydrate thereof or a pharmaceutically acceptable salt and ester thereof, a...
|
|
WO/2017/187319A1 |
Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
|
|
WO/2017/181857A1 |
A composition for fat reduction and liver protection, a preparation method thereof, and a pharmaceutical product comprising same. The composition comprises: Radix Astragali, Radix Puerariae, and Cortex Mori. The mass ratio of Radix Astra...
|
|
WO/2017/183028A1 |
The present invention provides compositions and methods for treating fibromyalgia syndrome (FMS). Specifically, the present invention provides anti eotaxin-2 antibodies for treating FMS.
|
|
WO/2017/178856A1 |
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of neuromuscular diseases, including motor neuron diseases like amyotrophic lateral sclerosis.
|
|
WO/2017/181014A1 |
The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystroph...
|
|
WO/2017/179225A1 |
Provided is a composition which can effectively suppress or improve physical hypofunction observed with age or physical dysfunction occurring with age, or mental hypofunction observed with age or mental dysfunction occurring with age, sa...
|
|
WO/2017/181015A1 |
The invention provides for recombinant AAV vectors comprising a miniaturized human micro-dystrophin gene and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.
|
|
WO/2017/180976A1 |
Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising β-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystr...
|
|
WO/2017/177945A1 |
Uses of a poria cocos extract, a tumulosic acid and/or a pharmaceutically acceptable salt of the tumulosic acid in the preparation of a drug or food, and the drug or the food is used for protecting muscles. The drug is especially used fo...
|
|
WO/2017/178315A1 |
This invention relates to the use of a composition comprising a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis (strain) 420 (B420), and one or more prebi...
|
|
WO/2017/179707A1 |
The present invention provides a novel combination for improving frailty or a novel combination for suppressing reduction in skeletal muscle mass. More specifically, the present invention provides a combination for improving frailty or a...
|
|
WO/2017/175181A1 |
The present invention relates to the quantification of various soluble proteins, including angiogenin in aqueous humor and plasma of patients with AMD. The invention further describes the role of angiogenin in the pathogenesis, progressi...
|
|
WO/2017/170926A1 |
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...
|
|
WO/2017/173234A1 |
A method for treating a subject suffering from a motor neuron degenerative disorder is provided herein, the method including: administering to the subject one or more modified adeno-associated virus (AAV) gene delivery vectors packaging ...
|
|
WO/2017/170924A1 |
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...
|
|
WO/2017/170830A1 |
Provided is a compound having an MAGL-inhibiting effect, and anticipated to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amy...
|
|
WO/2017/163076A1 |
The invention relates to inhibitors of CDK12 (cyclin-dependent kinase 12), and there use in the treatment or prevention of a disorder in a subject caused by the generation of repeat expansion transcripts.
|
|
WO/2017/162870A1 |
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity i...
|
|
WO/2017/158190A1 |
The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected fr...
|
|
WO/2017/159380A1 |
The purpose of the present invention is to provide a method for producing an upper motor neuron from a pluripotent stem cell, and a pluripotent stem cell which can be converted into an upper motor neuron. This method comprises a step for...
|
|
WO/2017/152744A1 |
The present invention provides a specific protein composition and a method for using the same. The composition is mainly a mixture of human rabies immunoglobulin (HRIG) and human tetanus immunoglobulin (HTIG), wherein the HRIG has an ant...
|
|
WO/2017/150477A1 |
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...
|
|
WO/2017/150228A1 |
The present invention addresses the problem of providing an efficacious means against muscle atrophy. Provided is a muscle atrophy inhibitor that comprises, as active ingredient(s): (1) one or more proteins selected from the group consis...
|
|
WO/2017/147505A1 |
Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.
|
|
WO/2017/144977A1 |
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
|
|
WO/2017/146053A1 |
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...
|
|
WO/2017/142054A1 |
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...
|
|
WO/2017/141911A1 |
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...
|
|
WO/2017/130151A1 |
The present invention relates to nucleotides, analogs of mRNA 5'-end (cap) containing sulfur atom at the position 5' of 7-methylguanosine nucleoside. The disclosed compounds are recognized (bound and non-hydrolyzed) by DcpS enzyme (Decap...
|
|
WO/2017/130190A1 |
This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such...
|
|
WO/2017/131149A1 |
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...
|
|
WO/2017/132410A1 |
The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disc...
|
|
WO/2017/131169A1 |
[Problem] The purpose of the invention is to provide a drug useful in the prophylaxis or treatment of muscle damage. [Solution] The invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccin...
|
|
WO/2017/126645A1 |
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...
|
|
WO/2017/121333A1 |
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especial...
|
